The coincidence of chromosome 15 aberrations and β2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

Clinical Cancer Research

Volumn 12, Issue 11 I, 2006, Pages 3297-3305

  Paschen, Annette ^a,b   Arens, Norbert ^b   Sucker, Antje ^a   Greulich Bode, Karin M ^a   Fonsatti, Ester ^c   Gloghini, Annunziata ^d   Striegel, Sandra ^a   Schwinn, Nicole ^a   Carbone, Antonino ^e   Hildenbrand, Ralf ^b   Cerwenka, Adelheid ^a   Maio, Michele ^c,d   Schadendorf, Dirk ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CHROMOSOMAL INSTABILITY; CHROMOSOME 15Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS; MICROSATELLITE MARKER; PRIORITY JOURNAL; TUMOR CELL;

BETA 2-MICROGLOBULIN; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 15; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION; TUMOR ESCAPE;

EID: 33745220023     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2174     Document Type: Article

References (38)

1. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99: 16168-73.
2. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immune-editing: from immune-surveillance to tumor escape. Nat Immunol 2002;3:991-8.
4. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
5. Sato T, McCue P, Masuoka K, et al. Interleukin 10 production by human melanoma. Clin Cancer Res 1996;2: 1383-90.
6. Ahmadzadeh M, Rosenberg SA. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005;174:5215-23.
7. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-16.
8. Ferrone S, Marincola FM. Loss o HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;487-94.
9. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
10. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 2004;16:644-50.
11. Jimenez P, Canton J, Collado A, et al. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999;83:91-7.
12. Geertsen R, Boni R, Blasczyk R, et al. Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations. Int J Cancer 2002; 99:82-7.
13. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003;195:346-55.
14. Goodfellow PN, Jones EA, Van Heyningen V, et al. The β2- microglobulin gene is on chromosome 15 and not in the HL-A region. Nature 1975;254:267-9.
15. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional β2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-8.
16. Benitez R, Godelaine D, Lopez-Nevot MA, et al. Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998;52:520-9.
17. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot β2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005;174: 1462-71.
18. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. β2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998;101:2720-9.
19. Perez B, Benitez R, Fernandez MA, et al. A new β2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999;53:569-72.
20. Paschen A, Mendez RM, Jimenez P, et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003;103:759-67.
21. Altomonte M, Gloghini A, Bertola G, et al. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993;53:3343-8.
22. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406-15.
23. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
24. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 1991;88:282-9.
25. Giacomini P, Natali P, Ferrone S. Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J Immunol 1985;135:696-702.
26. Speicher MR, Gwyn Ballard S, Ward DC. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996;12:368-75.
27. Greulich KM, Kreja L, Heinze B, et al. Rapid detection of radiation-induced chromosomal aberrations in lymphocytes and hematopoietic progenitor cells by mFISH. Mutat Res 2000;452:73-81.
28. Rodriguez T, Mendez R, Roberts CH, et al. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother 2005;54:141-8.
29. Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 2005;65:419-28.
30. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154: 745-54.
31. Giorda E, Sibilio L, Martayan A, et al. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Res 2003;63:4119-27.
32. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001;61:8647-50.
33. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to s defect in B2m gene expression. J Clin Invest 1991;87:284-92.
34. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: p2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 down-regulation in MSI-negative tumors. Tissue Antigens 2003;61:211-9.
35. Kloor M, Becker C, Benner A, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005;65:6418-24.
36. Schulten HJ, Gunawan B, Otto F, et al. Cytogenetic characterization of complex karyotypes in seven established melanoma cell lines by multiplex fluorescence in situ hybridization and DAPI banding. Cancer Genet Cytogenet 2002;133:134-41.
37. Hoglund M, Gisselsson D, Hansen GB, et al. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004;108:57-65.
38. Hoglund M, Frigyesi A, Sall T, Gisselsson D, Mitelman F. Statistical behavior of complex cancer karyotypes. Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 2005;42:327-41.